RARE FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. regarding misleading statements made about the efficacy of setrusumab in treating Osteogenesis Imperfecta, with a lead plaintiff deadline set for April 6, 2026 [1][5][6]. Group 1: Class Action Details - Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been initiated, and interested parties can join by submitting a form or contacting the law firm [3][7]. - The lawsuit claims that Ultragenyx provided materially false and misleading information regarding the expected results of its Phase III studies for setrusumab, which could have led to inflated stock prices [5][6]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in securities class action services [4]. Group 3: Case Specifics - The lawsuit alleges that Ultragenyx's management made overly optimistic statements about setrusumab's ability to reduce fracture rates in Osteogenesis Imperfecta patients while concealing material adverse facts about the drug's efficacy [6]. - It is claimed that the Phase III studies were less likely to demonstrate the claimed benefits than management suggested, leading to potential investor losses when the true information became public [6].